T. Rowe Price Investment Management, Inc. Ascendis Pharma A/S Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 30,564 shares of ASND stock, worth $4.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,564
Previous 2,568,903
98.81%
Holding current value
$4.36 Million
Previous $388 Million
98.93%
% of portfolio
0.0%
Previous 0.24%
Shares
8 transactions
Others Institutions Holding ASND
# of Institutions
223Shares Held
56.5MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.44 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$709 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$613 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$599 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$560 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.97B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...